GSK321 treatment of primary AML cells with mutant IDH1 uniformly led to the induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells, in vitro and in vivo, together with a decrease in intracellular oncometabolite 2-hydroxyglutarate [71]. Here, IDH1 is linked to acute myeloid leukemia.